Galectin-3 and prediction of therapeutic response to renal sympathetic denervation. (18th May 2016)

• Record Type: Journal Article
• Authors: Schwerg, Marius; Eilers, Björn; Wienecke, Anja; Baumann, Gert; Laule, Michael; Knebel, Fabian; Stangl, Karl; Stangl, Verena
• Is Part Of: Clinical and experimental hypertension. Volume 38:Number 4(2016)
• Page Start: 399
• Page End: 403
• Publication Date: 2016-05-18
• Subjects: Galectin-3 -- renal denervation -- resistant arterial hypertension; Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.3109/10641963.2016.1148157
• Languages: English
• ISSNs: 1064-1963

Abstract

ABSTRACT: The profibrotic mediator Galectin-3 (Gal-3) has been associated with aldosterone-mediated vascular inflammation, fibrosis, and stiffness. We evaluated whether the Gal-3 levels and change in Gal-3 as associated with renal denervation can serve as prediction of therapeutic response to renal denervation. A total of 42 patients with resistant hypertension undergoing renal sympathetic denervation (RDN) were included. Blood pressure was evaluated by 24-h ambulatory measurement before RDN and 1, 3 and 6 months after RDN. Treatment response was defined as a drop in systolic ambulatory blood pressure of >5 mm Hg after 6 months. Blood samples were assessed for Gal-3 levels. For the entire group, a significant drop in mean systolic ambulatory blood pressure of 5.2 ± 18.6 mm Hg was observed ( p = 0.032). The responder rate was 50% ( n = 21). At baseline, Gal-3 levels were significantly higher in responders (14.5 ± 6.0 vs. 10.95 ± 4.6 ng/ml, p = 0.017). There were no significant changes of Gal-3 levels during the follow-up period. The profibrotic biomarker may help to identify patients suitable for RDN.